Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | PHASE1 | RECRUITING | 90 | — | — | Jun 21, 2024 | Jun 1, 2028 | May 22, 2026 | 18 | United States, Australia +2 |
Incidence of dose-limiting toxicities and frequency of adverse events
| Arm | Type | Description |
|---|---|---|
| CTX310 | EXPERIMENTAL | Subjects will receive an intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| CTX310 | DRUG | CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3). |
Key Inclusion Criteria: 1. Age of ≥18 and ≤75 years at the time of signing the informed consent. 2. Able to provide written informed consent. 3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL i...